Drug intelligence / Profile preview

PRIM-DJ2727

Development stage: Phase 2
Lead developer: University of Texas Health Science Center at Houston
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Colonoscopy, Enema

Overview

**PRIM-DJ2727** is an investigational, donor-derived fecal microbiota transplantation product developed by The University of Texas Health Science Center at Houston. It is manufactured as a lyophilized intestinal-microbiota powder, generally administered in oral enteric-coated capsules, using stool from healthy screened donors. Rather than acting through a single molecular target, PRIM-DJ2727 is intended to restore or remodel recipient gut microbial communities and associated intestinal metabolic and immune functions. It has been evaluated in clinical studies across recurrent *Clostridioides difficile* infection, Parkinson's disease, HIV infection, ulcerative colitis, systemic sclerosis-associated constipation or bloating, metabolic dysfunction-associated steatotic liver disease, and alcoholic hepatitis. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/48/NCT03298048/Prot_SAP_000.pdf))

Other names: Lyophilized Fecal Microbiota Productfecal microbiota product粪微生态制品FMP

Beyond the preview

Go deeper on PRIM-DJ2727.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRIM-DJ2727.

Explore the full profile